TherapeuticsMD - TXMD Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings or view top-rated stocks.

TherapeuticsMD's stock was trading at $5.59 at the beginning of the year. Since then, TXMD stock has decreased by 37.0% and is now trading at $3.52.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our TXMD earnings forecast.

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($5.50) earnings per share for the quarter, missing analysts' consensus estimates of ($5.00) by $0.50. The business earned $25.41 million during the quarter, compared to analysts' expectations of $26.65 million. During the same quarter in the previous year, the business earned ($5.00) EPS.

TherapeuticsMD shares reverse split on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD's stock is owned by many different institutional and retail investors. Top institutional investors include Tejara Capital Ltd (3.37%), Simplex Trading LLC (0.00%), Morgan Stanley (1.42%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Geode Capital Management LLC (0.71%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends.

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXMD stock can currently be purchased for approximately $3.52.

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $33.16 million and generates $86.95 million in revenue each year. The company earns $-172,410,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

The company employs 416 workers across the globe.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389.